{
    "nct_id": "NCT05123703",
    "official_title": "A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis",
    "inclusion_criteria": "* Body weight â‰¥ 25 kilograms (kg)\n* Diagnosis of RRMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric Multiple Sclerosis (MS), Version 2012, or McDonald criteria 2017\n* Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive\n* For all countries except Germany, at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of at least one Gd enhancing lesion on MRI within 6 months\n\nInclusion Criteria for Optional OLE Period:\n\n-Participants in Group A (ocrelizumab in the double-blind period [DBP]) and Group B (fingolimod in the DBP) who, in the opinion of the investigator, may benefit from switching to ocrelizumab and who have completed the DBP with study treatment (ocrelizumab/fingolimod), may participate in the OLE period\nHealthy volunteers allowed\nMust have minimum age of 10 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Known presence or suspicion of other neurologic disorders that may mimic MS\n* Significant uncontrolled somatic diseases, known active infection or any other significant condition that may preclude participant from participating in the study\n* Participants with severe cardiac disease or significant findings on the screening Electrocardiograph (ECG)\n\nExclusion Criteria for Optional OLE Period:\n\n-Participants who have discontinued the study during the DBP",
    "miscellaneous_criteria": ""
}